PTCT
PTC Therapeutics, Inc.
stockNASDAQ
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc's discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc's internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 60.59 | 2026-10-23 | -1.02% | 3.218 |
| 1M | 64.13 | 2026-10-01 | -6.49% | 2.151 |
| 3M | 68.01 | 2026-07-31 | -11.82% | 1.095 |
| 6M | 65.15 | 2026-05-01 | -7.95% | 0.506 |
| 1Y | 68.31 | 2025-10-31 | -12.21% | 0.789 |
| 2Y | 39.92 | 2024-10-31 | +50.23% | — |
| 5Y | 39.32 | 2021-11-01 | +52.52% | 0.975 |
PTC Therapeutics, Inc. (NASDAQ:PTCT) stock price today is $59.97, and today's volume is 2,357,646. PTCT is down 6.966% today. The 30 day average volume is 1.14M. PTCT market cap is $5.01B with 83.46M shares outstanding.